Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Assets Average (2016 - 2025)

Historic Assets Average for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to $30.1 million.

  • Northwest Biotherapeutics' Assets Average rose 453.55% to $30.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.1 million, marking a year-over-year increase of 453.55%. This contributed to the annual value of $27.3 million for FY2024, which is 776.34% down from last year.
  • As of Q3 2025, Northwest Biotherapeutics' Assets Average stood at $30.1 million, which was up 453.55% from $28.5 million recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Assets Average registered a high of $35.4 million during Q1 2022, and its lowest value of $27.1 million during Q1 2025.
  • Its 5-year average for Assets Average is $30.1 million, with a median of $29.7 million in 2023.
  • Its Assets Average has fluctuated over the past 5 years, first surged by 22966.31% in 2021, then plummeted by 1209.15% in 2024.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Assets Average stood at $34.2 million in 2021, then decreased by 8.72% to $31.2 million in 2022, then fell by 4.91% to $29.7 million in 2023, then decreased by 5.57% to $28.0 million in 2024, then grew by 7.33% to $30.1 million in 2025.
  • Its Assets Average stands at $30.1 million for Q3 2025, versus $28.5 million for Q2 2025 and $27.1 million for Q1 2025.